These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 26804906)

  • 41. MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.
    de Leeuw R; McNair C; Schiewer MJ; Neupane NP; Brand LJ; Augello MA; Li Z; Cheng LC; Yoshida A; Courtney SM; Hazard ES; Hardiman G; Hussain MH; Diehl JA; Drake JM; Kelly WK; Knudsen KE
    Clin Cancer Res; 2018 Sep; 24(17):4201-4214. PubMed ID: 29739788
    [No Abstract]   [Full Text] [Related]  

  • 42. Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.
    Long F; He Y; Fu H; Li Y; Bao X; Wang Q; Wang Y; Xie C; Lou L
    Cancer Sci; 2019 Apr; 110(4):1420-1430. PubMed ID: 30724426
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.
    Gomatou G; Trontzas I; Ioannou S; Drizou M; Syrigos N; Kotteas E
    Mol Biol Rep; 2021 Jan; 48(1):915-925. PubMed ID: 33409716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer.
    Yuan Y; Wen W; Yost SE; Xing Q; Yan J; Han ES; Mortimer J; Yim JH
    Sci Rep; 2019 May; 9(1):7509. PubMed ID: 31101835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
    Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
    J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.
    Paternot S; Colleoni B; Bisteau X; Roger PP
    Cell Cycle; 2014; 13(18):2879-88. PubMed ID: 25486476
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Abemaciclib sensitizes HPV-negative cervical cancer to chemotherapy via specifically suppressing CDK4/6-Rb-E2F and mTOR pathways.
    Liu Y; Zhao R; Fang S; Li Q; Jin Y; Liu B
    Fundam Clin Pharmacol; 2021 Feb; 35(1):156-164. PubMed ID: 32446293
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
    Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
    Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The CDK4/6 inhibitor PD0332991 stabilizes FBP1 by repressing MAGED1 expression in pancreatic ductal adenocarcinoma.
    Zhang B; Li D; Jin X; Zhang K
    Int J Biochem Cell Biol; 2020 Nov; 128():105859. PubMed ID: 32987196
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
    Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
    Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.
    Qie S; Yoshida A; Parnham S; Oleinik N; Beeson GC; Beeson CC; Ogretmen B; Bass AJ; Wong KK; Rustgi AK; Diehl JA
    Nat Commun; 2019 Mar; 10(1):1296. PubMed ID: 30899002
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest.
    Goel S; DeCristo MJ; McAllister SS; Zhao JJ
    Trends Cell Biol; 2018 Nov; 28(11):911-925. PubMed ID: 30061045
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
    Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
    Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer.
    Knudsen ES; Kumarasamy V; Chung S; Ruiz A; Vail P; Tzetzo S; Wu J; Nambiar R; Sivinski J; Chauhan SS; Seshadri M; Abrams SI; Wang J; Witkiewicz AK
    Gut; 2021 Jan; 70(1):127-138. PubMed ID: 32424005
    [TBL] [Abstract][Full Text] [Related]  

  • 56. B cell antigen receptor-mediated activation of cyclin-dependent retinoblastoma protein kinases and inhibition by co-cross-linking with Fc gamma receptors.
    Tanguay D; Pavlovic S; Piatelli MJ; Bartek J; Chiles TC
    J Immunol; 1999 Sep; 163(6):3160-8. PubMed ID: 10477583
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma.
    Song X; Liu X; Wang H; Wang J; Qiao Y; Cigliano A; Utpatel K; Ribback S; Pilo MG; Serra M; Gordan JD; Che L; Zhang S; Cossu A; Porcu A; Pascale RM; Dombrowski F; Hu H; Calvisi DF; Evert M; Chen X
    Clin Cancer Res; 2019 Jan; 25(1):403-413. PubMed ID: 30084835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
    Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
    Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies.
    Xu XQ; Pan XH; Wang TT; Wang J; Yang B; He QJ; Ding L
    Acta Pharmacol Sin; 2021 Feb; 42(2):171-178. PubMed ID: 32504067
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The transcriptome of CDK4/6 inhibition.
    Knudsen ES; Witkiewicz AK
    Aging (Albany NY); 2017 Aug; 9(8):1859-1860. PubMed ID: 28860413
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.